Loading...
Docoh

Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

Company profile

Ticker
IOVA
Exchange
Website
CEO
Maria Fardis
Employees
Incorporated
Location
Fiscal year end
Former names
FREIGHT MANAGEMENT CORP, Genesis Biopharma, Inc, Lion Biotechnologies, Inc.
SEC CIK
Subsidiaries
Iovance Biotherapeutics GmbH, a company • Iovance Biotherapeutics B.V., a company • Iovance Biotherapeutics Manufacturing LLC, a limited liability company ...
IRS number
753254381

IOVA stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 114.51M 114.51M 114.51M 114.51M 114.51M 114.51M
Cash burn (monthly) (no burn) (no burn) 33.24M 31.43M 25.88M 21.91M
Cash used (since last report) n/a n/a 101.68M 96.13M 79.15M 67.03M
Cash remaining n/a n/a 12.83M 18.38M 35.36M 47.48M
Runway (months of cash) n/a n/a 0.4 0.6 1.4 2.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Aug 22 Mcpeak Merrill A Common Stock Option exercise Acquire M No No 5.65 40,000 226K 60,150
23 Aug 22 Mcpeak Merrill A Stock Option Common Stock Option exercise Acquire M No No 5.65 40,000 226K 0
14 Jun 22 Bilinsky Igor Common Stock Payment of exercise Dispose F No No 7.73 9,346 72.24K 9,504
14 Jun 22 Bilinsky Igor Common Stock Option exercise Acquire M No No 0 18,850 0 18,850
14 Jun 22 Bilinsky Igor RSU Common stock Grant Acquire A No No 0 18,850 0 18,850
14 Jun 22 Finckenstein Friedrich Graf Common Stock Payment of exercise Dispose F No No 7.73 6,809 52.63K 12,881
14 Jun 22 Finckenstein Friedrich Graf Common Stock Option exercise Acquire M No No 0 19,690 0 19,690
14 Jun 22 Finckenstein Friedrich Graf RSU Common stock Grant Acquire A No No 0 19,690 0 19,690
14 Jun 22 Jean-Marc Bellemin Common Stock Payment of exercise Dispose F No No 7.73 9,346 72.24K 9,504
14 Jun 22 Jean-Marc Bellemin Common Stock Option exercise Acquire M No No 0 18,850 0 18,850
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: AACR, advisory, anaplastic, biodiversity, body, carbon, caution, climate, comprised, cybersecurity, death, description, drought, energy, equitable, ESG, exacerbated, flooding, friendly, frontline, gas, greenhouse, heat, implied, inventory, leveraging, met, outreach, plastic, poster, precisely, procurement, proliferation, proxy, publicly, reaction, recyclability, referenced, reopen, Score, sea, serve, spoilage, stewardship, stimulate, strive, superseded, text, triple, unmet, upgrade, waste, water, weather, withheld
Removed: achieved, cleared, cut, dialog, driver, finalized, inhibitory, reviewed, speak

Patents

Utility
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
6 Sep 22
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Utility
Methods and Compositions for Selecting Tumor Infiltrating Lymphocytes and Uses of the Same In Immunotherapy
11 Aug 22
The present invention provides improved methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for selecting TILs responsive to a mutant polypeptide expressed by cancer cells and not expressed in normal tissue.
Utility
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
2 Aug 22
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Utility
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
12 Jul 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Utility
Processes for Generating Til Products Enriched for Tumor Antigen-specific T-cells
30 Jun 22
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.

Reddit threads